Science & Technology
A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4R44CA291622-02
Award Ceiling
$627K
Award Floor
$627K
Close Date
Apr 30, 2028
777 days leftTotal Funding
$627K
Expected Awards
1
Posted Date
May 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-4R44CA291622-02
Description
SBIR Phase Phase II award: "A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients" awarded to Syntrix Biosystems, Inc. in Auburn, Washington. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $627,270. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.